. 2006 Sep;1(3):255–262.

Table 2.

Efficacy of pegylated interferon alpha-2a on hepatitis B e Antigen positive chronic hepatitis B virus patients

	Pegylated interferon alpha-2a plus placebo (n = 271)	Pegylated interferon alpha-2a plus lamivudine (n = 271)	Lamivudine (n = 272)
Co-primary endpoints
HBeAg	32% (p < 0.001)^a	27% (p = 0.023)	19%
seroconversion
HBV DNA < 100 000 copies/mL	32% (p = 0.012)^a	34% (p = 0.003)^a	22%
Secondary endpoints
HBeAg loss	34% (p < 0.001)^a	28% (p = 0.043)^a	21%
ALT normalization	41% (p = 0.002)^a	39% (p = 0.006)^a	28%

compared with lamivudine therapy.